Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Olamkicept Part B

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 1/2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05104723Phase 1/2Completed

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

NCT06298032Phase 1Completed

A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons

Showing all 2 trials

Research Network

Common Treatments

  • Olamkicept Part B1
  • Olamkicept Part A1
  • Tofacitinib1

Active Sponsors

  • Ferring Pharmaceuticals1
  • Ferring Pharmaceuticals A/S1
  • National Institute of Allergy and Infectious Diseases (NIAID)1

Top Investigators

Related Conditions

  • Inflammatory Skin Disease1
  • Inflammatory Gastrointestinal Diseases1
  • Chronic Granulomatous Disease1
  • Inflammatory Lung Disease1

Activity Timeline